Objective: Harnessing the regenerative capabilities of stem cell-derived exosomes holds great promise for developing novel hair growth therapies, offering hope for individuals experiencing hair loss or alopecia. This aimed to elucidate the effect of “foreskin-derived mesenchymal stromal cells derived exosome” injection into the scalp on hair density in patients with androgenetic alopecia and the contribution of this treatment on patient satisfaction. Method: This prospective study included 30 male patients, aged between 22 and 65, with hair type III-VI according to the Norwood-Hamilton scale. Characterization of the stem cell exosomes was performed with the nanoparticle tracking analysis (NTA), hair densities were calculated via digital imaging analysis, and patient satisfaction was questioned with a modified survey. Results: NTA results showed a characteristic distribution of peaks for exosomes 139.7 ± 2.3 nm in diameter. A statistically significant increase in hair density was observed in the 4th and 12th weeks after treatment (p < 0.05). Patient-reported satisfaction revealed a statistically significant difference in the answers given in the 12th week compared to the 4th week (p < 0.05). No side effects or complications were observed after exosome injection. Conclusion: Foreskin-derived mesenchymal stromal cells derived exosome injection increased hair density, with sustained patient satisfaction throughout the study. The exosome application resulted in no side effects. Level of Evidence IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
1 January 2020 in Case Reports in Plastic Surgery and Hand Surgery
Silent Sinus Syndrome is a rare syndrome that usually involves the maxillary sinus. In this case report, we present a rare case diagnosed as Silent Sinus Syndrome with frontal, ethmoid and maxillary sinus involvement which was presented with periorbital complaints after the rhinoplasty operation performed in our clinic.
Three-dimensional (3D) simulation and virtual reality (VR) technologies are increasingly used in aesthetic surgery consultations to enhance decision-making and expectation management. However, their impact on surgical decision-making and postoperative satisfaction across different procedures remains unclear. This study aimed to evaluate the influence of 3D simulation and VR technology in patients undergoing rhinoplasty, breast augmentation, mastopexy, augmentation-mastopexy and breast reduction. A retrospective study was conducted with 75 female patients who underwent primary aesthetic surgery. Preoperative 3D simulations and VR visualizations were generated using the Crisalix Virtual Esthetics system (Crisalix S.A., Switzerland). Patients were assessed postoperatively at one year using structured surveys to evaluate the influence of 3D simulation and VR technology on their decision-making and satisfaction. Statistical analyses included the Kruskal-Wallis H test, the Chi-Square test, and Spearman's correlation. 3D simulation had the greatest influence on breast augmentation (8.4/10), rhinoplasty (7.6/10), and augmentation-mastopexy (7.1/10) patients but was less impactful for mastopexy (6.6/10) and breast reduction (3.8/10) patients (p < 0.001). The most decisive factors were previous patient photos (30.7%) and communication with the surgeon (29.3%), with simulation ranking third (18.7%). Postoperative similarity ratings were highest in breast augmentation (7.9/10) and rhinoplasty (7.5/10) patients. While 70.7% of patients would recommend 3D simulation, VR headset use did not influence decisions (p < 0.001). 3D simulation enhances patient engagement and expectation management across various aesthetic procedures. While its influence is more significant in surgeries primarily focused on aesthetic outcomes, it serves as a complementary tool rather than a definitive factor in decision-making.
Background: While various analgesic methods have been proposed in breast augmentation, limited data exist comparing their efficacy in a controlled setting. This prospective, split-body study aimed to compare the effectiveness of preoperative PECS I block and intraoperative direct local anesthetic infiltration for postoperative pain control following breast augmentation. Methods: Twenty female patients (ASA I–II, aged 18–59) undergoing bilateral breast augmentation with identical implants via dual-plane or submuscular approaches were included. Each patient received a PECS I block on the right breast (10 mL of 0.5% bupivacaine) performed preoperatively by the same anesthesiologist. The left breast received an identical dose via direct local anesthetic infiltration administered by the same plastic surgeon prior to muscle transection. Postoperative pain was evaluated using the Numeric Rating Scale (NRS) at 30 min intervals for the first 2 h, every 2 h between 2 and 6 h, at 24 h, on postoperative day 5, and at 3 months. Results: Pain scores were significantly lower on the PECS I block side compared to the local infiltration side during the early postoperative period (30 min to 6 h) ( p < 0.05). No significant difference was observed at 24 h, day 5, or 3 months. The mean tramadol requirement in the first 6 h was 72.0 ± 10.05 mg, with a total of 171.0 ± 21.98 mg at 24 h. Conclusions: In this split-body study, PECS I block provided superior pain control during the early postoperative period (first 6 h) compared to direct local infiltration. Level of Evidence II: Evidence Based Medicine Level: Evidence Level II, Therapeutic Study. This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
25 December 2025 in European Journal of Breast Health
The superomedial pedicle technique combines aesthetic advantages with reliable vascularity in reduction mammaplasty. This study evaluated the safety and clinical outcomes of Doppler ultrasonography-guided identification of the superior perforator in the superomedial pedicle design. This retrospective study included 22 female patients who underwent bilateral superomedial pedicle reduction mammaplasty between April 2023 and April 2025. In all patients, the superior perforator was detected preoperatively using a portable handheld Doppler ultrasonography device and was incorporated into the pedicle design. All patients underwent surgery via an inverted-T pattern with the superomedial pedicle. The mean follow-up period was 1.2 years. The superior perforator was identified in all patients (mean time: 3.0±0.4 minutes). No partial or total necrosis of the nipple-areola complex was observed in any patient. Wound dehiscence occurred at the T-incision site in four patients, transient areolar hypoesthesia was observed in three patients, and hypertrophic scarring developed in one patient. Aesthetic outcomes were evaluated in all patients by physical examination and standardized photography. Detection of the superior perforator with Doppler ultrasonography enables individualized planning of the superomedial pedicle and enhances vascular safety. This approach provides a feasible, individualized, and reliable surgical technique for reduction mammaplasty, thereby reducing complication rates.